Central Nervous System Diseases
3
Pipeline Programs
5
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Chong Kun Dang PharmaceuticalKorea - Seodaemun
1 program1
Memantine Tab. 10mgPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Chong Kun Dang PharmaceuticalMemantine Tab. 10mg
BraccoProHance
BraccoMultiHance
Clinical Trials (3)
Total enrollment: 497 patients across 3 trials
CKD-355 Drug-drug Interaction Study (CKD-355 DDI P1)
Start: Apr 2018Est. completion: Jun 201820 patients
Phase 1Completed
Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs
Start: Nov 2018Est. completion: Oct 2019125 patients
N/ACompleted
Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients
Start: May 2017Est. completion: Mar 2018352 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
5 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.